Merck, a prominent science and technology company, has disclosed that its Life Science business sector has initiated a non-binding Memorandum of Understanding (MoU) with Mycenax Biotech. The purpose of this collaboration is to explore potential cooperation in introducing advanced and high-capacity bioprocessing solutions to international markets, with a particular focus on Taiwan. The MoU outlines plans for incorporating Merck’s BioContinuum™ Platform across the entire bioprocessing spectrum for Mycenax’s clientele, with subsequent steps involving the automation and digitalization of processes.
Gladys Wang, Head of Process Solutions, South Asia & Oceania, Life Science business sector at Merck, commented on the transformative impact of digitalization in biomanufacturing. She highlighted the shift towards a data-intensive, interconnected, and seamlessly continuous processing facility of the future. The collaboration between Merck and Mycenax, particularly in Contract Development and Manufacturing Services, is aimed at expediting the development of novel products and process innovations to fortify resilience in both research and production.
Within the framework of the MoU, Merck will explore providing comprehensive support to Mycenax, including consultation, technical assistance, and training, to ensure optimal performance. The collaboration will also emphasize the incorporation of in-depth cost modeling to enhance process economics, recognizing the significance of economic viability in the partnership. This strategic analysis is intended to improve cost-effectiveness in the realm of next-generation bioprocessing.
Dr. Pei-Jiun Chen, Chairman/CEO and President of Mycenax, expressed the company’s commitment to seeking optimal solutions and areas for optimization. Acknowledging the future trend of integrating continuous processing and Industry 4.0, Dr. Chen emphasized the collaboration’s goal of providing innovative continuous processing solutions to enhance Mycenax’s international standing and address diverse biopharmaceutical needs.
About Merck
Merck, a leading science and technology company, operates across life science, healthcare and electronics. More than 64,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2022, Merck generated sales of € 22.2 billion in 66 countries.
Source: https://www.sigmaaldrich.com/LK/en/collections/press/mou-mycenax-biotech
